Beyfortus (nirsevimab) / AstraZeneca, Sanofi - LARVOL DELTA

Factors Associated with Nirsevimab Receipt for Respiratory Syncytial Virus Prophylaxis Among Asian and Pacific Islander Infants in Hawaii (PAS 2025) - "Design/ We performed a retrospective chart review of newborns at a hospital in Honolulu, Hawaii discharged between December 2023 and May 2024 who qualified for Nirsevimab by hospital policy: infants with Medicaid insurance, whose mothers did not receive RSV prophylaxis within 2 weeks before delivery, and who did not qualify for Palivizumab per AAP guidelines. Of 1,011 eligible newborns, only 52.9% received Nirsevimab. Native Hawaiian (aOR 4.30, 95% CI [1.56, 11.89]) and Other Pacific Islander (aOR 4.81, 95% CI [2.14, 10.81]) newborns were more likely to receive Nirsevimab than Caucasians. Newborns residing in the Windward district of Oahu island were less likely (aOR 0.25, 95% CI [0.10, 0.63]) to receive Nirsevimab than newborns residing in Honolulu."

Hepatitis B • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Uptake of Nirsevimab in Infants Aged 0-12 Months in San Diego County During the 2023-2024 RSV Season (PAS 2025) - "Infants who received nirsevimab within one week of admission or after admission, those who received palivizumab, and those whose mothers received maternal RSV vaccine were excluded. Several racial minority groups (Asian, Hawaiian/Pacific Islander, and Multi-racial; OR=1.4, 1.9, 1.2; p< 0.001, p< 0.001, p< 0.05) were more likely to have received nirsevimab compared to the reference group of Whites. There was a negative relationship between healthy places index (HPI) and receipt of nirsevimab (highest HPI vs lowest, OR = 0.85, p < 0.05). 250 of 572 infants admitted to RCHSD for bronchiolitis during the study period tested positive for RSV via PCR."

Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Infant RSV immunoprophylaxis: A single center’s experience with early adoption of nirsevimab for all infant protection in Syracuse, New York (PAS 2025) - "Among those hospitalized, only 2 (13%) had received nirsevimab and 1 was receiving monthly doses of palivizumab. We identified 598 patients who were eligible to receive RSV IP. Of these, 295 (49%) received IP. The average age of administration was 74.4 days old (range: 0-406 days)."

Clinical • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Summary of the National Advisory Committee on Immunization (NACI) Statement on the Prevention of Respiratory Syncytial Virus (RSV) in Infants. (PubMed, Can Commun Dis Rep) - "Immunization programs for the prevention of respiratory syncytial virus (RSV) in infants have been available in Canada since the authorization of palivizumab in 2002...Currently, nirsevimab is preferred over RSVpreF. Program introduction could occur in stages depending on access to supply, cost effectiveness, and affordability of available options."

Journal • Critical care • Respiratory Diseases • Respiratory Syncytial Virus Infections

Sanofi’s quarterly profit boosted by Dupixent and newer drugs; forecast unchanged (Reuters) - "France's Sanofi...reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines....Sales of Beyfortus, a new treatment to protect newborns from a common respiratory virus, jumped 54.9% to 284 million euros, compared with analysts' estimate of 215 million euros."

Sales • Respiratory Syncytial Virus Infections

A New Era in RSV Prevention (PAS 2025) - "A buffet dinner will be provided to attendees preregistered for the symposium. Learning Objectives: •Recognize the burden of RSV disease in infants •Understand nirsevimab, a long-acting antibody administered to newborns and older infants for RSV prevention •Identify best practices regarding implementation of nirsevimab in both the newborn nursery and outpatient settings"

Respiratory Syncytial Virus Infections

RSV Protection for Neonates Before Hospital Discharge (PAS 2025) - "Implementation was supported by institutional culture and required drug addition to inpatient formulary, VFC enrollment, pharmacy IT and infrastructure to allocate VFC or INSUR nirsevimab-alip stock to appropriate infants, and multidisciplinary education (Table 1). Implementation occurred in two phases (Table 2). The first phase (Nov 2023 - Jan 2024) was focused in the ICU, with 147 discharges (24-41 weeks gestation, birth weight 585-4579g) among whom 78% had RSV protection, primarily nirsevimab-alip."

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Respiratory Diseases • Respiratory Syncytial Virus Infections

Demographic Characteristics that Influence the Uptake of Neonatal RSV Prophylaxis in a Single Military Treatment Facility (PAS 2025) - "571 of 583 infants met inclusion criteria. 455 (~80%) had adequate RSV prophylaxis by discharge of their birth hospitalization (Table 1). There was more uptake of RSV prophylaxis in infants whose mothers were active duty/reserve/guard versus dependent/retiree status (84% vs."

Pediatrics • Respiratory Syncytial Virus Infections

Improving Nirsevimab Uptake in the Ambulatory Care Network (PAS 2025) - "Nirsevimab uptake increased from 0% to a cumulative average of 52% of eligible infants < 8 months throughout the October 2023-March 2024 season (Fig 2). Conclusion(s): Coordination between the pharmacy staff, newborn medicine departments, newborn clinic, and ambulatory sites was necessary to ensure coverage of more than 50% of our patients under age 8 months in the first season of offering nirsevimab. This is compared to suboptimal rates across New York City which were an average of 6.6% coverage for the 2023-2024 season of infants under 8 months."

Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Nirsevimab Administration to Infants in the Neonatal Intensive Care Unit (NICU): A Single-Center Experience (PAS 2025) - "During the 2023-24 RSV season, 173 of 367 infants received nirsevimab before NICU discharge. Reasons for not receiving nirsevimab included maternal RSV vaccination during pregnancy, transfer to higher level NICU, and parental hesitancy. Ten (6%) of the 173 infants (gestational ages from 24-36 weeks) had A/B/D (n=7) or decrease in PO ≥ 20% (n=3) following nirsevimab administration."

Clinical • Bronchopulmonary Dysplasia • Cardiovascular • Critical care • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumococcal Infections • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Predictors of Nirsevimab Uptake Across a Large Pediatric Primary Care Network (PAS 2025) - "Of 7208 eligible patients, 2534 (35%) received nirsevimab, ranging from 20%-65% across practices. Full cohort characteristics provided in Table 1. After adjustment, receipt of nirsevimab was associated with age at start of RSV season, race, and practice location (Figures 2 and 3)."

Clinical • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Nirsevimab uptake among eligible infants in a pediatric primary care network during the 2023-2024 RSV season (PAS 2025) - "Thirty-eight percent of eligible infants received nirsevimab during the 2023-2024 RSV season. The median age at time of receipt was 1 month. Among infants who received nirsevimab, 69% identified as Black/African American, 15% as White, and 14% as Hispanic/Latino."

Clinical • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Effectiveness of Nirsevimab in preventing RSV infections and hospitalizations in infants following routine administration in the United States: a national retrospective cohort study (PAS 2025) - No abstract available

Retrospective data • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Challenges in RSV Prevention in Japan: Limited Access to Nirsevimab and Cost Barriers for Maternal Vaccination (PAS 2025) - No abstract available

Respiratory Syncytial Virus Infections

Nirsevimab and RSV Vaccine Implementation in the U.S.: Achieving Universal Infant and Maternal Coverage (PAS 2025) - No abstract available

Respiratory Syncytial Virus Infections

How to Protect Children Around the World from Respiratory Syncytial Virus (RSV) (PAS 2025) - "The discussion will cover the epidemiology of RSV in different regions and the use of nirsevimab and maternal RSV vaccines, with insights from the U.S., Japan, and Vietnam...Upon completion, participants will be able to identify gaps in RSV prevention strategies, including monoclonal antibodies and vaccines, in Western and Asian healthcare systems. Upon completion, participants will be able to evaluate the potential future use of RSV monoclonal antibodies and vaccines for high-risk groups, including immunocompromised patients."

Clinical • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Disparities in Receipt of Nirsevimab and Maternal RSV Vaccine: Insights from the Initial Rollout (PAS 2025) - No abstract available

Respiratory Syncytial Virus Infections

Developing a Proactive Care Payment Model to Incentivize and Reduce the Cost of Nirsevimab Immunization in Primary Care (PAS 2025) - No abstract available

Clinical

Past, present and future of respiratory syncytial infection prevention in infants and young children. (PubMed, Expert Opin Pharmacother) - No abstract available

Journal • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Global Pediatric Pulmonology Alliance recommendations to protect all infants against respiratory syncytial virus with prophylactic monoclonal antibodies. (PubMed, Pediatr Investig) - No abstract available

Journal • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

EVALUATING THE PUBLIC HEALTH IMPACT OF INFANT RSV PROPHYLAXIS PROGRAMS IN SPAIN AND THE UK: PRELIMINARY RESULTS FROM THE REACH STUDY (ESPID 2025) - "The UK has implemented maternal vaccine to prevent RSV in infants from autumn 2024/5 whereas Spain implemented nirsevimab monoclonal antibody treatment in 2023/4 and 2024/5... Amongst infants <12 months of age, the cumulative number of RSV hospitalizations, based on ICD-10 coded data, was reduced by 79.5% in Spain and 24.1% in the UK compared to the 22/23 (pre-prophylaxis) season, up until latest data cut-off (31-Dec-2022 vs. 31-Dec-2024). Amongst infants <6 months of age, the reduction was 85.7% in Spain and 28.4% in UK."

Late-breaking abstract • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

REACTOGENICITY AND IMMUNOGENICITY OF INVESTIGATIONAL MRNA-1345 IN 8- TO 11-MONTH-OLD CHILDREN WITH AND WITHOUT PRIOR NIRSEVIMAB EXPOSURE (ESPID 2025) - "Conclusions/Learning Points No increase in RSV-A/B nAbs was observed following vaccination in the nirsevimab group, whereas a robust rise was observed in the non-nirsevimab group. The potential impact of prior nirsevimab receipt on active RSV vaccination immunogenicity necessitates evaluation of this interaction for all candidate paediatric RSV vaccines."

Clinical • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

EPIDEMIOLOGY OF ADMISSIONS DUE TO BRONCHIOLITIS IN ENGLAND 2013-2023 - A SOCIOECONOMIC ANALYSIS (ESPID 2025) - "Whilst many countries have chosen a postnatal vaccination strategy with Nirsevimab, in Autumn 2024 the UK introduced maternal vaccination against RSV using Abrysvo...Conclusions/Learning Points An effective RSV vaccine will reduce not only morbidity and mortality in children, but also costs for the health service. We will present 10 years worth of data encompassing every paediatric admission with RSV, highlighting changing patterns of admissions and treatments, along with a cost effectiveness analysis of the new RSV vaccine."

Clinical • HEOR • Omic analysis • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

IMPACT OF A MIXED STRATEGY OF MONOCLONAL ANTIBODY AND MATERNAL IMMUNIZATION ON PEDIATRIC RSV HOSPITALIZATIONS IN LUXEMBOURG, 2022-2024 (ESPID 2025) - "Background After the successful rollout of nirsevimab immunization in 2023, Luxembourg was among the first countries to implement a mixed strategy offering free maternal vaccination or nirsevimab immunization starting in September 2024...We found no signal of increased hospitalizations in children immunized in the previous season 2023/24. Maternal vaccination and infant immunization had similar effectiveness in preventing RSV-hospitalizations."

Clinical • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

TRANSFORMING TRENDS: THE CHANGING LANDSCAPE OF INFECTIONS IN CHILDREN OVER EIGHT YEARS (ESPID 2025) - "Conclusions/Learning Points This comprehensive analysis reveals that, after 2023, the situation has largely stabilized to pre-COVID conditions. However, the anticipated introduction of Nirsevimab for newborns and infants under 1 year of age marks a groundbreaking advancement, poised to redefine the landscape of preventive care in this vulnerable population."

Clinical • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Pneumonia • Preventive care • Respiratory Diseases • Respiratory Syncytial Virus Infections